Exelixis, Inc. (NASDAQ: EXEL) investors are cheering this morning as the stock is headed for the top. The gains are ultimately the result of an announcement that the company’s partner has received European Commission approval for a partnered product. Of course, this news is exciting investors who are pushing the stock up. Today, we’ll talk … Read more
After releasing its earnings early this morning, Exelixis, Inc. (NASDAQ: EXEL) is making a run for the top in the market this morning, The company’s earnings beat expectations in a big way, exciting investors who are pushing the stock for the top as we speak. Today, we’ll talk about: The financial results; what we’re seeing … Read more
Exelixis, Inc. (NASDAQ: EXEL) is having an overwhelmingly strong start to the trading session this morning, and for good reason. The company announced that the FDA has granted Priority Review surrounding one of the company’s pipeline treatments. Of course, this led to excitement among investors, sending the stock screaming for the top. As is normally … Read more
Exelixis, Inc. (NASDAQ: EXEL) is off to a strong start in the pre-market hours this morning after announcing that it has completed the submission of a supplemental New Drug Application, also known as sNDA. As a result, investor excitement ensued, leading to gains in the stock and prompting our partners at Trade Ideas to alert … Read more
Exelixis, Inc. (NASDAQ: EXEL) Exelixis is having an incredibly rough day in the market today. As soon as the opening bell rang, the stock started to make a run for the bottom. Throughout the first hour, we’ve seen more of the same movement, bringing the value further and further down. Below, we’ll talk about what … Read more
Exelixis, Inc. (NASDAQ: EXEL) Exelixis is having an incredibly strong day in the market today after reporting positive news from a key Phase 2 clinical trial. Today, we’ll talk about the data that was released, how the stock reacted to the news, and what we can expect to see from EXEL ahead. Trade smarter and … Read more
Exelixis, Inc. (NASDAQ: EXEL) Exelixis is having an incredibly strong day in the market today, and for good reason. The company announced incredibly positive trial results surrounding its lead candidate. Today, we’ll talk about the results, how the market reacted to the news, and what we can expect to see from EXEL moving forward. So, … Read more
Exelixis, Inc. (NASDAQ: EXEL) Exelixis is having an incredible day in the market today, and for good reason. The company announced data from a pivotal Phase 2 clinical trail, and the data was overwhelmingly positive. Today, we’ll talk about the trial results, how the market reacted to the news, and what we can expect to … Read more
Exelixis, Inc. (NASDAQ: EXEL) Exelixis is having an incredible time in the market at the moment, and for a good reason. The company recently received overwhelmingly positive news from the FDA, exciting investors. Today, we’ll talk about the news that was received, how the market is reacting to the news, and what we can expect … Read more
Exelixis, Inc. (NASDAQ: EXEL) Exelixis is having an incredible day in the market today, and for good reason. The company announced that it has reached an exclusive licensing agreement for the commercialization and development of the company’s lead drug. Today, we’ll talk about the licensing agreement, how the market reacted to the news, and what … Read more